Company profile: NeoImmuneTech
pharmaphorum
NOVEMBER 29, 2022
Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. Creation: Jan. Areas of expertise: Immuno-Oncology.
Let's personalize your content